The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Abstract
CONTEXT: Second-generation (atypical) antipsychotics (SGAs) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be more effective, with fewer adverse effects, and preferable to patients. Most evidence comes from short-term efficacy trials of symptoms. OBJECTIVE: To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are associated with improved quality of life across 1 year compared with FGAs. DESIGN: A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 weeks using intention-to-treat analysis. SETTING: Fourteen community psychiatric services in the English National Health Service. PARTICIPANTS: Two hundred twenty-seven people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects. INTERVENTIONS: Randomized prescription of either FGAs or SGAs (other than clozapine), with the choice of individual drug made by the managing psychiatrist. MAIN OUTCOME MEASURES: Quality of Life Scale scores, symptoms, adverse effects, participant satisfaction, and costs of care. RESULTS: The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded. Participants in the FGA arm showed a trend toward greater improvements in Quality of Life Scale and symptom scores. Participants reported no clear preference for either drug group; costs were similar. CONCLUSIONS: In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Neither inadequate power nor patterns of drug discontinuation accounted for the result.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Multiple imputation in health‐are databases: An overview and some applications
Rubin, D. B., & Schenker, N. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100410 · Cited by 1,550
A depression rating scale for schizophrenics
Addington, D., Addington, J., & Schissel, B. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90005-r · Cited by 1,269
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Self-citationA Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.1.99 · Cited by 511
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Self-citationRosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Measures of quality of life among persons with severe and persistent mental disorders
Lehman, A. F. (1996) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00801903 · Cited by 320
Melkersson, K. I., Hulting, A.-L., & Brismar, K. E. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 299
VORUGANTI, L., HESLEGRAVE, R., AWAD, A. G., & SEEMAN, M. V. (1998) · Psychological Medicine · doi:10.1017/s0033291797005874 · Cited by 260
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Voruganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S., & Awad, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00154-1 · Cited by 226
The Barnes Akathisia Rating Scale–Revisited
Barnes, T. R. E. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103174013 · Cited by 179
Self-citationA systematic review of atypical antipsychotic drugs in schizophrenia
Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gilbody, S., Davies, L., Torgerson, D., & Kleijnen, J. (2003) · Health Technology Assessment · doi:10.3310/hta7130 · Cited by 178
Self-citationThe pharmacology of weight gain with antipsychotics.
Casey, D. E., & Zorn, S. H. (2001) · PubMed · Cited by 164
Intervention Research in Psychosis: Issues Related to the Assessment of Quality of Life
Awad, A. G., & Voruganti, L. N. P. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033477 · Cited by 118
Quality of Life in Schizophrenia: A Comparison of Instruments
Cramer, J. A., Rosenheck, R. A., Xu, W., Thomas, J. V., & Henderson, W. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033484 · Cited by 110
Medication Self-Management: A preliminary report on an intervention to improve medication compliance
Hayward, P. (1995) · Journal of Mental Health · doi:10.1080/09638239550037343 · Cited by 99
Adams, C. E. (2004) · Psychiatric Bulletin · doi:10.1192/pb.28.9.351 · Cited by 83
Kilian, R., Dietrich, S., Toumi, M., & Angermeyer, M. C. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00332.x · Cited by 34
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
“High CTAM 0.147 � 0.172, 0.466 8.49 (4), not significant 5 347 � 0.058, 0.782 Low CTAM 0.509 0.221, 0.797 23.04 ( 9 ), significant at the 5% level 10 520”
Influential
Metadata
- Authors
- Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-10-01
- Volume
- 63
- Issue
- 10
- Pages
- 1079
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109196233
- Cited by
- 1,105
- References
- 32
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.